Brands
Oral JAK inhibitors unlikely to be totally shut out in eczema by black box warning
Why has the WHO asked governments to delay Covid-19 booster jabs?
Insurers to squeeze JAK inhibitor access in chronic conditions after FDA safety warning
EU approval of Novartis’ Kesimpta offers treatment that can be self-administered, but Roche’s Ocrevus will retain MS market position
Boehringer Ingelheim reports positive business growth in 2020
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
